BN.PA
T3Danone S.A.
OverviewDanone provides health-focused food through three segments: dairy and plant-based products, specialized medical and infant nutrition, and bottled waters. Dairy
Danone provides health-focused food through three segments: dairy and plant-based products, specialized medical and infant nutrition, and bottled waters. Dairy and plant-based items contribute 52% of revenue, specialized nutrition 31%, and waters 17%. They sell primarily to grocery retailers, hospitals, and pharmacies, serving everyday consumers and patients who need specific dietary support for their health.
- What They Do (Plain English & Analogies)
- Danone is a global food and beverage leader focused on "Health through Food." Think of them as the "biological software" provider for the human body; they don't just sell calories, they sell functional nutrition. If a general food conglomerate like Nestle is a massive supermarket, Danone is the specialized health-food and pharmacy aisle. They provide essential nutrition for every life stage: from specialized formula for infants to high-protein recovery snacks for athletes and medical-grade tube feeding for hospital patients.
- Very Brief History
- Founded in 1919 by Isaac Carasso in Barcelona to treat children's intestinal disorders with yogurt. It merged with French glassmaker BSN in 1973, eventually pivoting to a pure-play food company. After years of underperformance and activist pressure, CEO Antoine de Saint-Affrique launched the "Renew Danone" strategy in 2022 to fix execution, rotate the portfolio, and reinvest in core brands like Activia and Evian, leading to the current "Chapter 2" phase focused on high-growth medical and functional nutrition.
- "Street Stereotype"
- Historically viewed as the "sleepy laggard" of European staples due to bloated costs and weak execution in the US and China. However, the narrative has shifted to a "successful turnaround story." Investors now see it as a disciplined "value compounder" that is outperforming peers like Nestle in volume growth, though recent safety recalls in infant formula in early 2026 have reintroduced some skepticism regarding operational consistency.
- Subsidiaries On Linked In*
- Nutricia, Alpro, Evian, Volvic, Happy Family Organics, Blédina, Aqua, Danone North America, Danone Manifesto Ventures.
- Customer Sectors & Example Clients
- 1. Mass Retail: Global giants like Walmart, Carrefour, Tesco, Kroger, and Ahold Delhaize. 2. Healthcare: Hospitals, clinics, and nursing homes (supplying medical nutrition like Fortimel and Nutrison). 3. Specialized Retail/E-commerce: Tmall and JD.com in China, and pharmacy chains like Walgreens or Boots. 4. Away-from-Home: Gyms, offices, and convenience stores (selling drinkable yogurts and protein shakes).
- New Customers / Segments They'Re Targeting
- Danone is aggressively targeting GLP-1 medication users by offering high-protein, fiber-enriched products (like Oikos Fusion) to preserve muscle mass and support digestive health. They are also gunning for the "Aging Population" through Medical Nutrition and expanding their "Away-from-Home" footprint in gyms and offices to reach busy professionals with meal replacements like Alpro Meal To Go.
- How Key Themes May Help/Hurt
- The "Healthy Foods" and "GLP-1" themes are major tailwinds, as Danone's high-protein (Oikos, YoPro) and gut-health (Activia) platforms gain market share from sugary snacks. However, the company is highly sensitive to the "Food Safety" theme; the 2026 infant formula recall in Europe highlights the risk that regulatory compliance shifts or reputational damage can temporarily offset structural growth drivers.
3 Main Long-Term Bull Details
- Medical Nutrition Powerhouse: The acquisition of Kate Farms and the integration of Nutricia create a high-margin, $500M+ platform in the US, tapping into structural demand from aging populations and clinical nutrition. 2. Volume-Led Growth: Unlike peers struggling with pricing fatigue, Danone is delivering consistent volume/mix growth (+2.7% in 2025), proving strong brand equity in Europe and China. 3. Functional Leadership: Danone is the global leader in gut health and high-protein dairy, categories that are less discretionary and benefit from the massive GLP-1/wellness trend.
3 Main Long-Term Bear Details
- Reputation and Recall Risk: The 2026 Infant Milk Formula recall in Europe and the Middle East creates a one-off sales hit (0.5-1% in Q1 2026) and risks damaging the trust required in the premium Aptamil brand. 2. North American Execution: The company continues to struggle with underperformance in US plant-based (Silk) and coffee creamers (International Delight), requiring leadership changes and heavy reinvestment. 3. Demographic Headwinds: Despite winning market share, the core Infant Milk Formula business faces a long-term ceiling due to declining birth rates in key markets like China.
- Competitors And Differentiation
- Main competitors include Nestle, Unilever, Abbott Laboratories (in Medical Nutrition), and Reckitt (in Infant Formula). Danone differentiates itself by being a "pure-play" health company; nearly 90% of its portfolio has a Health Star Rating of 3.5 or higher. Unlike generalists, Danone focuses on biotics, high-quality protein, and medical-grade science to justify premium pricing and functional claims.
- Recent Performance & What The Market'S Focused On
- Danone delivered a strong 2025 with 4.5% LFL sales growth and a recurring operating margin of 13.4%. However, the market is currently hyper-focused on the Q1 2026 impact of the Infant Milk Formula recall and the progress of the leadership change in North America. Investors are looking for proof that the US turnaround will take hold by Q2 2026 and that the IMF issues are contained without long-term brand damage.
- Brands And Revenue Segments
- 1. Essential Dairy & Plant-Based (EDP) [~52% of Rev]: Activia, Oikos, Danone, Silk, Alpro, YoPro, International Delight. 2. Specialized Nutrition [~31% of Rev]: Aptamil, Nutrilon, Neocate (Infant); Fortimel, Nutrison, Kate Farms (Medical). 3. Waters [~17% of Rev]: Evian, Volvic, Mizone, Aqua, Bonafont.
Bull / Bear DetailsAs of February 23, 2026, Danone is successfully transitioning into a high-quality compounder, evidenced by its 10.7% ROIC and consistent volume-led growth (+2.7
Thesis
As of February 23, 2026, Danone is successfully transitioning into a high-quality compounder, evidenced by its 10.7% ROIC and consistent volume-led growth (+2.7% in FY25). While recent Infant Milk Formula recalls in Europe present a temporary Q1 2026 headwind, the company's pivot toward high-margin Medical Nutrition and functional dairy platforms like Oikos PRO remains the primary value driver. Danone's ability to fix North American execution while scaling science-based innovation makes it a compelling turnaround story.
Bull case
Specialized and Medical Nutrition have become high-margin growth engines, with the Kate Farms acquisition creating a $500 million platform in the U.S. and providing critical hospital access. In China, Danone continues to outperform the market through its premium Aptamil Essensis range, while global Medical Nutrition demand remains robust, driven by aging demographics and the clinical recognition of nutritional support for faster patient recovery.
Danone is a primary beneficiary of the health-focused consumer shift, with billion-euro platforms in High Protein and Plant-based (Oikos, Alpro) delivering double-digit growth. The launch of Oikos Fusion, specifically designed for GLP-1 users to preserve muscle mass and gut health, demonstrates the company's agility in capturing emerging dietary trends. Sustained volume/mix growth in Europe EDP for nine consecutive quarters validates the successful revitalization of legacy brands.
Financial discipline and operational transformation are yielding results, with ROIC now firmly in double-digit territory at 10.7%. The Industry 5.0 initiative, leveraging AI for predictive maintenance and automated quality systems, is driving productivity gains to fund brand reinvestment. With a deleveraged balance sheet and a shift toward high-growth channels like pharmacies and home care, Danone is well-positioned for strategic, accretive acquisitions that align with its health-centric strategy.
Bear case
The recent industry-wide Infant Milk Formula recalls in Europe and the Middle East create significant near-term uncertainty, with management projecting a 50-100 basis point hit to Q1 2026 group sales. Beyond the immediate financial impact, the sensitive nature of the category carries the risk of brand equity damage and consumer hesitancy, which could hinder the momentum of Danone's highest-margin segment in key Western markets.
Execution in North America remains a persistent concern, as the Coffee Creamers and Plant-based segments underperformed in late 2025 due to capacity constraints and intense competition. While leadership changes have been made, the business is reliant on a successful recovery starting in Q2 2026. Failure to reclaim lost shelf space for International Delight and Silk could lead to permanent market share erosion in a critical geography.
Structural demographic headwinds, specifically low birth rates in China and Europe, continue to cap the long-term growth potential of the Infant Milk Formula category. Competitors are responding with aggressive product giveaway programs and deep discounting to stimulate demand, which threatens to trigger a price war and compress margins. Relying on temporary birth-rate stabilization or Dragon Year boosts may mask underlying structural category declines.
Bull / Bear Case
- Bear Case
- Significant execution and reputational risks persist. The North American segment underperformed in late 2025 (+0.7% Q4 LFL), with market share losses in Coffee Creamers and Plant-based products due to service disruptions and intense competition. More critically, the recent Infant Milk Formula (IMF) recalls in Europe and the Middle East are expected to shave 50-100 basis points off Group Q1 2026 sales, potentially damaging long-term brand equity in a high-trust category. While China is currently strong, the structural decline in birth rates and aggressive competitor 'giveaway' programs pose long-term margin risks. Furthermore, the Essential Dairy & Plant-Based (EDP) segment's recurring operating margins remain below 10%, as productivity gains are being entirely consumed by the need for defensive reinvestment to maintain category relevance and reclaim leadership in gut health.
- Bull Case
- Danone is successfully transitioning into a high-quality compounder under its 'Renew Chapter 2' strategy. FY2025 results demonstrated resilient 4.5% like-for-like (LFL) growth, crucially powered by a +2.7% volume/mix contribution—outperforming many global peers currently struggling with pricing fatigue. The company achieved a milestone double-digit ROIC of 10.7% and generated €2.8 billion in free cash flow. Key growth engines include the €1 billion+ High Protein platforms (Oikos, HiPro) and a rapidly scaling Medical Nutrition business, now a $500 million platform in the U.S. following the Kate Farms acquisition. Management's focus on 'Industry 5.0' and AI-driven productivity is successfully funding heavy reinvestment into brand superiority. Furthermore, China remains a standout performer (+11.7% LFL), proving Danone can win in premium Specialized Nutrition despite broader demographic headwinds.
- More Compelling & Why
- Bull. Danone's ~6.8% FCF yield and forward P/E of ~14.2x represent a significant discount to historical averages and peers like Nestlé, despite Danone delivering superior volume-led growth (+2.7%). The strongest argument is the structural shift toward Medical Nutrition and High Protein, which are high-margin, science-backed categories less prone to private-label trade-down. The IMF recall is a manageable one-off event (0.5-1% Q1 hit) that appears priced in given the stock's muted reaction. I would flip to Bear if North American volume fails to recover by Q2 2026 or if the IMF recall leads to sustained market share erosion in Europe.
Key Factors
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| GLP-1 Product Traction (Oikos Fusion & High Protein) | Danone is positioning itself as a GLP-1 beneficiary. The launch of Oikos Fusion (protein + fiber) specifically targets muscle preservation and gut health for weight-loss drug users, a key emerging growth demographic. | Sales performance of Oikos Fusion in the U.S. and HiPro in Europe. Monitor management's commentary on 'GLP-1 companion' product sell-through rates. | Double-digit growth in Oikos/HiPro platforms = Bullish (validates the 'Health-Focused' portfolio pivot); Stagnation in high-protein yogurt share = Bearish. | Quarterly earnings presentations; Industry conferences (e.g., Consumer Analyst Group of New York - CAGNY). | Social Media (TikTok/Instagram): Mention frequency of 'Oikos' or 'HiPro' in 'GLP-1 diet' or 'high protein' hashtags. | YipitData: E-commerce market share for high-protein yogurt and meal replacement categories. |
| Volume/Mix Growth Threshold (2.5%+ Target) | As pricing tailwinds fade (2.1% in Q4 2025), Danone's thesis relies on volume-led growth. Maintaining Volume/Mix above 2.5% proves brand health and the success of the shift toward high-protein and gut-health platforms. | The 'Volume/Mix' component of LFL sales growth across all regions, particularly Europe EDP, which has seen 9 consecutive quarters of positive volume. | Volume/Mix > 2.7% (FY25 level) = Bullish (indicates structural market share gains); Volume/Mix < 2.0% = Bearish (suggests consumer trade-down to private label). | Quarterly earnings press releases (Sales Bridge section). | Tmall/JD.com: Monthly sales rankings for Mizone and Aptamil in China to proxy volume momentum. | Consumer Edge: Credit card spending data on Danone brands vs. category averages in key European markets. |
| Medical Nutrition Scaling (Kate Farms Integration) | Medical Nutrition is a high-growth, high-margin pillar. The acquisition of Kate Farms created a $500M platform in the U.S. with access to hospital infrastructure, which is critical for long-term valuation rerating. | Kate Farms LFL growth rate (currently 'strong double digits') and its consolidation into LFL figures starting Q3 2026. Watch for expansion into Tier 2/3 hospitals in China. | Sustained >10% LFL growth in Specialized Nutrition (Medical sub-segment) = Bullish; Deceleration to <7% = Bearish (suggests integration friction or hospital procurement headwinds). | Quarterly financial reports; Press releases regarding new hospital contracts or clinical study results for Fortimel/Nutrison. | LinkedIn: Hiring trends for Danone's 'Medical Affairs' and 'Hospital Sales' teams in North America and China. | Thinknum: Job posting growth for specialized nutrition sales representatives; IQVIA: Hospital procurement data for enteral and oral nutrition products. |
| Infant Milk Formula (IMF) Recall Impact (Q1 2026) | Management quantified a one-off impact of 50-100 basis points on Group Q1 2026 sales due to recalls in Europe and the Middle East. As a high-margin segment, any prolonged supply disruption or brand equity erosion could derail the 'Renew' strategy's margin expansion goals. | Q1 2026 Specialized Nutrition LFL sales growth and management's update on shelf replenishment timing in Europe. Watch for EFSA (European Food Safety Authority) follow-up statements regarding the 'low to moderate' risk assessment. | If Q1 Group LFL impact exceeds 100 bps = Bearish (indicates deeper brand damage); If impact is contained within 50 bps and shelves are fully replenished by end of March 2026 = Bullish. | Q1 2026 Trading Update (expected April 2026); EFSA official publications; National food safety authority press releases in France and UK. | Google Trends: Search volume for 'Aptamil recall' or 'Danone safety' in European markets; Retailer websites (Tesco, Carrefour) for 'Out of Stock' labels on IMF products. | NielsenIQ: Weekly market share and 'All Commodity Volume' (ACV) distribution levels for Aptamil in France, UK, and Germany. |
| North American Coffee Creamer Recovery (Q2 2026) | North America underperformed in 2025 (+2% LFL) due to capacity constraints and competition in creamers. Management identified Q2 2026 as the inflection point when easier comparables and new capacity for International Delight come online. | Market share data for International Delight and Silk in the US. Monitor the rollout of the 'Two Good' clean-label creamer range and 'Danimals' relaunch performance. | Positive Volume/Mix in North America EDP by Q2 2026 = Bullish (validates leadership changes and capacity investments); Continued negative volume in Noram EDP = Bearish. | Q1 and Q2 2026 Earnings Calls; US retail scanner data reports. | Walmart.com/Target.com: Customer review sentiment and 'Best Seller' rankings for International Delight vs. Coffee Mate. | Numerator: Consumer switching data between Danone creamers and private label/Nestle competitors; Placer.ai: Foot traffic in US grocery dairy aisles. |
Key Reported Metrics
| Metric | Why It Matters | Last Period |
|---|---|---|
| North America LFL Sales Growth | Following a disappointing performance in late 2025, the market is looking for signs of recovery in coffee creamers and plant-based products. Success depends on leadership changes and new production capacity coming online to reclaim lost market share. | +0.7% |
| Specialized Nutrition LFL Sales Growth | As Danone's highest-margin segment, its performance is critical for margin expansion. Investors are watching the impact of European recalls and the sustainability of premium growth in China to justify a valuation rerating toward high-growth nutrition peers. | +10.1% |
| Like-for-Like (LFL) Sales Growth | Investors are monitoring if Danone can maintain its 3-5% guidance despite a 50-100 bps headwind from IMF recalls in Q1 2026. Sustained organic growth validates the 'Renew Danone' strategy and its ability to navigate a weak consumer environment through volume-led momentum. | +4.7% |
Key QuestionsCan Danone successfully contain the financial impact of the Infant Milk Formula recalls to the guided 50-100 basis point hit in Q1 2026 and restore consumer tru
Can Danone successfully contain the financial impact of the Infant Milk Formula recalls to the guided 50-100 basis point hit in Q1 2026 and restore consumer trust in Europe without experiencing long-term market share loss?
- Question 2
Will the organizational changes and new production capacity in North America be sufficient to reverse the underperformance in Coffee Creamers and Plant-based segments by Q2 2026, or is the competitive landscape permanently impaired?
- Question 3
Can Danone maintain its high-quality, volume-led growth (targeting 2.5%+ volume/mix) while delivering on its promise of recurring operating income growing faster than sales, particularly as it reinvests heavily in the EDP segment?
Rerating Thresholds
| Metric | What'S Needed For Rerating | Why It Matters | Earnings Date |
|---|---|---|---|
| Like-for-Like (LFL) Sales Growth | Danone needs to achieve sustained LFL sales growth in the 4.5% to 5.0% range, specifically driven by a Volume/Mix contribution of at least 2.5%. This would exceed the current 4.2% level and sit at the top end of management's 3-5% medium-term guidance, outperforming peers like Nestlé. | Achieving volume-led growth at the high end of guidance validates the 'Renew Danone' strategy and its positioning as a GLP-1 beneficiary. Consistent volume gains prove brand equity and market share capture, justifying a valuation multiple expansion to close the historical discount versus global consumer staple peers. | 2026-02-20 |
| Volume/Mix Growth | To achieve a significant valuation rerating, Danone needs to sustain Volume/Mix growth consistently within the 3.5% to 4.5% range. While the current 3.6% is robust, investors require proof that this volume-led momentum is structural rather than a temporary recovery. Specifically, Danone must continue to outperform peers like Nestlé and Unilever in volume metrics while maintaining positive pricing power, effectively hitting the upper bound of its 3-5% like-for-like (LFL) sales growth guidance through volume gains in its 'Essential Dairy & Plant-Based' and 'Specialized Nutrition' segments. | Volume-led growth validates Danone's 'Renew Danone' strategy and its competitive positioning in a GLP-1-influenced market. Consistent outperformance in volume suggests market share gains and brand health, shifting investor perception from a low-growth laggard to a high-quality compounder, which justifies a higher P/E multiple relative to its historical average. | 2026-02-20 |
| Specialized Nutrition LFL Sales Growth | Specialized Nutrition LFL sales growth needs to reach or exceed 6.0%. This requires sustaining high-single-digit growth in Medical Nutrition (7%+) and maintaining positive momentum in China Infant Nutrition despite demographic headwinds. Surpassing the current 5.2% and the analyst consensus of 4.5-5.0% is necessary to signal structural acceleration and justify a valuation multiple expansion toward premium nutrition peers. | As Danone's highest-margin segment, Specialized Nutrition is the primary driver of the 'Renew Danone' margin expansion strategy. Achieving 6%+ growth validates the company's pivot toward high-growth medical nutrition and GLP-1 support products, shifting investor sentiment from a legacy dairy producer to a high-value health and wellness leader. | 2026-02-20 |
Earnings Transcript Summary
· 2025FY Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 1. Scaling High-Growth Health Platforms: Management is doubling down on 'billion-euro platforms' in High Protein (Oikos, HiPro), Gut Health (Activia), and Medical Nutrition (Kate Farms), which are driving volume-led growth. 2. Operational Transformation (Industry 5.0): Focusing on digitizing the end-to-end value chain, using AI for predictive maintenance and automated quality systems to drive productivity gains. 3. Fixing North American Performance: Addressing underperformance in Coffee Creamers and Plant-based segments through leadership changes (new Zone President Henri Bruxelles) and capacity expansion to meet demand. | Overall Takeaway: Danone delivered a strong 2025, meeting its 'Renew Chapter 2' goals with 4.5% LFL growth and a significant ROIC improvement to 10.7%. The company is successfully pivoting toward a volume-led model driven by medical nutrition and functional dairy, though it faces near-term headwinds from IMF recalls and a needed turnaround in the U.S. Tone: Confident, disciplined, and execution-oriented, with a clear focus on 'constructive dissatisfaction' to fix underperforming areas. | Q3 2025 LFL Growth: Total Group: +4.2%; Specialized Nutrition: +5.2%; Essential Dairy & Plant-Based (EDP): +3.8%; Waters: +3.4%. (Note: Total Group and Specialized Nutrition accelerated in Q4/FY, while EDP and Waters saw slight deceleration compared to Q3). | 1. Infant Milk Formula (IMF) Recall: Analysts questioned the financial and brand impact of recalls in Europe and the Middle East. Management responded that they expect a one-off Q1 2026 impact of 0.5% to 1% on group sales but remain confident in product safety and long-term brand trust. 2. EDP Margin Progression: Analysts pressed on why EDP margins remain below 10% despite volume growth. Management explained that while gross margins are improving, they are intentionally reinvesting heavily in brand superiority and innovation to reclaim category leadership. 3. North America Volume Softness: Analysts noted the soft Q4 performance in North America. Management attributed this to capacity constraints and competitive pressure in creamers, stating that recovery is expected from Q2 2026 as new capacity comes online and leadership changes take effect. | Total Group: +4.5% LFL; Specialized Nutrition: +7.4% LFL; Essential Dairy & Plant-Based (EDP): +3.5% LFL; Waters: +1.9% LFL. |
· 2025Q1 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 1. Volume-Led Growth: Management is prioritizing a shift toward volume/mix-driven growth (up +1.9% this quarter) to ensure long-term resilience as inflation-driven pricing fades. 2. Scaling High-Protein and Functional Platforms: They are doubling down on winning brands like HiPRO, Oikos PRO, and Activia Kefir, which are seeing double-digit growth and higher margins. 3. Channel Diversification: Focus is shifting toward 'Away-from-Home' and Medical/Pharmacy channels, which are growing 2x to 3x faster than traditional mass retail. | Overall Takeaway: Danone delivered a strong, broad-based beat to start 2025, characterized by a healthy balance between price and volume. The 'Renew Danone' strategy is clearly taking hold, particularly in the recovery of European EDP and the continued dominance of Specialized Nutrition in China. While US Coffee Creamers were a temporary soft spot, the acceleration in Medical Nutrition and high-protein segments provides a high-quality growth profile. Tone: Confident, disciplined, and execution-oriented. | In Q4 2024, LFL growth was: Total Group: +4.1%; EDP: +3.9%; Specialized Nutrition: +4.5%; Waters: +3.4%. Comparison: Specialized Nutrition and Waters accelerated in Q1 2025, while EDP saw a slight deceleration from the prior quarter's pace. | 1. North America Coffee Creamer Performance: Analysts questioned the slowdown and competitive pressure. Management responded that internal service disruptions and out-of-stocks caused the dip, but these are now resolved and distribution is being rebuilt. 2. Pricing Sustainability: Analysts asked if the Q1 pricing pickup (+2.4%) was a peak. Management clarified that this was influenced by technical factors like the leap year and weather-related promotional pauses in Waters, and they expect pricing to normalize. 3. China Infant Formula (IMF) Outlook: Analysts pressed on birth rate headwinds and competitor promotions. Management highlighted significant market share gains via the premium Essensis platform and noted 'green shoots' in Stage 1 (0-6 months) formula demand. | Essential Dairy and Plant-based (EDP): +3.7% LFL; Specialized Nutrition: +5.3% LFL; Waters: +4.1% LFL; Total Group: +4.3% LFL. |
Transcript Tidbits
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| Danone is aggressively expanding into specialized channels like pharmacies, hospitals, and home care, which delivered double-digit growth in 2025 and are outperforming mass retail. The acquisition of Kate Farms has created a $500 million Medical Nutrition platform in the U.S., providing critical access to hospital infrastructure. Additionally, the company consolidated its Australian dairy joint venture to 51% ownership and is expanding production capacity for High Protein, Skyr, and Medical Nutrition across Europe, China, the U.S., and Japan to capture emerging health trends. | In the China Infant Milk Formula (IMF) market, Danone is navigating a fragmented landscape where competitors have launched 'ambitious product giveaway programs' to stimulate growth. In North America, the company admitted to 'unsatisfactory performance' in Coffee Creamers and Plant-based segments, noting the need to 'double down' to bring International Delight back to its leading position. The recent industry-wide IMF recalls in Europe and the Middle East also created temporary shelf disruptions across multiple players. | Management believes the food industry is at a 'tipping point' where consumers increasingly view food and health as intertwined, specifically seeking nutrient-dense proteins and fibers. The China IMF category is entering a 'normalizing category context' following the 2024 'Dragon year boost.' Furthermore, Medical Nutrition is being recognized for its 'health economic benefits,' helping patients recover faster and reducing costs for healthcare systems. | For 2026, Danone is targeting like-for-like sales growth of +3% to +5% with recurring operating income growing faster than sales. The company is moving to the 'front foot on acquisition' with a focus on strategic health-focused fits. A major operational shift is underway via 'Industry 5.0,' which involves digitizing the value chain with AI-enabled planning hubs and automated quality systems. In the U.S., a recovery in the Coffee Creamers business is expected to begin in Q2 2026 as distribution is rebuilt. | Healthy | Industry 5.0 (AI-enabled manufacturing and predictive maintenance); GLP-1 influenced dietary shifts toward muscle preservation (protein) and gut health (fiber); Regenerative agriculture and supply chain resilience through the 'Danone Milk Academy.' | ROIC is now firmly anchored into double-digit territory.; Our categories continue to outperform the broader food and beverage industry.; Aptamil business doubled in Vietnam in just 1 year.; Medical Nutrition... demand remains very high. | In the U.S., our performance in '25 didn't meet our expectations.; Unsatisfactory performance of our Plant-based and Coffee Creamers business.; Supply disruption to have a one-off impact on our Q1 performance.; External environment remains uncertain. | The company is upskilling 20,000 employees globally through its 'Industry 5.0 Academy' and 'DanSkills' initiatives to prepare for digital and AI-enabled roles. Significant leadership changes were made in the North American zone, including a new Americas President and new category leads, to rebuild a 'culture of winning.' |
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| Danone is aggressively expanding into strategic channels outside of mass retail, such as away-from-home, pharmacies, and hospitals, which are growing 2x to 3x faster than legacy channels. The company is scaling its 'billionaire platform' in the away-from-home segment by introducing EDP formats like drinkable yogurts and is expanding its Medical Nutrition footprint in China by moving from Tier 1 hospitals into Tier 2 and Tier 3 locations. Additionally, they are enhancing digital execution and e-commerce distribution for infant milk formulas in China. | In North America, the Coffee Creamer category is facing 'strong competition' from both current market leaders and new incumbents, which was compounded by Danone's internal service disruptions and out-of-stock issues. In the China infant milk formula (IMF) market, competitors are launching 'ambitious product giveaway programs' to stimulate category growth, though Danone continues to gain share through its premium Essensis platform. | The broader industry is navigating a 'weak' consumer environment and 'uncertain times,' yet 'healthy nutrition' remains a dominant global trend. There is a noted stabilization in birth rates in China (the 'Year of the Dragon' effect) benefiting stage 1 formula, and a structural increase in at-home coffee consumption. Cost inflation is described as reaching a 'normal level,' driven by milk, labor, and logistics. | Danone confirmed its FY2025 guidance of 3% to 5% like-for-like sales growth, with recurring operating income expected to grow faster than sales. The company is shifting toward a volume-led growth model and intends to use its deleveraged balance sheet for strategic acquisitions. Management expects improved performance in the North American coffee segment in Q2 as distribution is rebuilt. | Healthy | Strategic channel diversification away from traditional retail; Digital-driven business models in emerging markets; GLP-1 influenced demand shifts toward high-protein and medical-grade nutrition. | Another quarter of quality growth, with like-for-like sales up plus 4.3%.; Medical Nutrition... demand remains very high.; Winning significant market share... in China.; Aptamil brand is again posting very strong growth. | Consumer which remains weak.; Slower start amidst an increasingly competitive environment.; Experienced service disruptions... resulting in temporary out-of-stock.; Negative impact from currency fluctuations. |
Earnings ResultsDanone successfully hit the lower end of the rerating target range for the full year, with Q4 showing even stronger momentum at 4.7%. Crucially, the growth was
| Metric | Prior Quarter | Rerating Trigger | Actual Reported | Hit Target? | Notes |
|---|---|---|---|---|---|
| Like-for-Like (LFL) Sales Growth | 4.2% | Danone needs to achieve sustained LFL sales growth in the 4.5% to 5.0% range, specifically driven by a Volume/Mix contribution of at least 2.5%. This would exceed the current 4.2% level and sit at the top end of management's 3-5% medium-term guidance, outperforming peers like Nestlé. | 4.5% LFL growth for FY 2025 (4.7% in Q4 2025) | Yes | Danone successfully hit the lower end of the rerating target range for the full year, with Q4 showing even stronger momentum at 4.7%. Crucially, the growth was supported by a 2.7% volume/mix contribution for the full year, exceeding the 2.5% threshold required for the rerating thesis. |
| Volume/Mix Growth | 3.6% | To achieve a significant valuation rerating, Danone needs to sustain Volume/Mix growth consistently within the 3.5% to 4.5% range. While the current 3.6% is robust, investors require proof that this volume-led momentum is structural rather than a temporary recovery. Specifically, Danone must continue to outperform peers like Nestlé and Unilever in volume metrics while maintaining positive pricing power, effectively hitting the upper bound of its 3-5% like-for-like (LFL) sales growth guidance through volume gains in its 'Essential Dairy & Plant-Based' and 'Specialized Nutrition' segments. | 2.7% for FY 2025 (2.5% in Q4 2025) | No | While volume/mix remained positive for the 9th consecutive quarter in Europe, the group-level figure decelerated from the 3.6% seen in the prior period and fell short of the 3.5%-4.5% rerating target. Management cited unsatisfactory performance in North American Coffee Creamers and Plant-based segments as a primary drag on volume momentum. |
| Specialized Nutrition LFL Sales Growth | 5.2% | Specialized Nutrition LFL sales growth needs to reach or exceed 6.0%. This requires sustaining high-single-digit growth in Medical Nutrition (7%+) and maintaining positive momentum in China Infant Nutrition despite demographic headwinds. Surpassing the current 5.2% and the analyst consensus of 4.5-5.0% is necessary to signal structural acceleration and justify a valuation multiple expansion toward premium nutrition peers. | 7.4% LFL growth for FY 2025 | Yes | This was a significant beat against the 6.0% rerating target. The segment was powered by double-digit growth in Medical Nutrition and strong premiumization in China (Aptamil). The acquisition of Kate Farms has created a $500 million platform, further cementing this segment as Danone's high-margin growth engine. |
Notes
| Date | Comment | Comment Type | Comment Sentiment | Link | IS CHANGE | Price Reaction |
|---|---|---|---|---|---|---|
| 2026-02-20 | Danone's FY25 results showed healthy 4.5% LFL growth and volume-led momentum. However, the market reacted cautiously, with the stock underperforming the SPY (-0.54% vs +0.72%). Sentiment was dampened by a significant Infant Milk Formula recall in Europe, projected to impact Q1 sales by 50-100 bps. Despite strength in Medical Nutrition and China, execution challenges in North American coffee creamers remain a key investor concern. | Earnings Transcript | Neutral | https://www.danone.com/investor-relations.html | False | -0.54% (vs SPY: -1.26%) |
Upcoming Events
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| BN.PA_b9252973 | in the course of the month of March | 2026-03-01 | 2026-03-31 | Normalization of Infant Milk Formula (IMF) supply and consumer trust in Europe and the Middle East following product recalls. | Management expects a one-off impact of 0.5% to 1% on Q1 2026 group net sales; successful normalization is critical to protecting long-term brand equity in the Specialized Nutrition segment. | Ticker | 2026-02-20 | |
| BN.PA_95546978 | from the second quarter [2026] onwards | 2026-04-01 | 2026-06-30 | Recovery and return to growth of the North American Coffee Creamers business (International Delight). | This segment has been an underperformer and a drag on North American margins; a successful turnaround is vital for the region to meet its 2026 growth and profitability targets. | Ticker | 2026-02-20 | |
| BN.PA_943e01a3 | from the third quarter of 2026 onwards | 2026-07-01 | 2026-09-30 | Inclusion of Kate Farms into Danone's like-for-like (LFL) sales growth calculations. | Kate Farms is a high-growth $500 million platform; its transition into organic growth metrics will provide a meaningful tailwind to North American and Specialized Nutrition LFL performance. | Ticker | 2026-02-20 | |
| BN.PA_5a86a725 | gearing up for the 2026 season | 2026-03-01 | 2026-08-31 | Launch of multiple product renovations for the Mizone brand in China ahead of the peak summer season. | Mizone is a critical driver for the Waters segment in China; successful seasonal execution is necessary to maintain the high-growth momentum of the CNAO region. | Ticker | 2026-02-20 | |
| BN.PA_b1c4ae08 | progressively allow us to capture growth [throughout 2026] | 2026-04-01 | 2026-12-31 | Incremental rollout of new production capacity for High Protein, Skyr, Kefir, and Medical Nutrition across the U.S., Europe, China, and Japan. | New capacity is intended to resolve current out-of-stock issues in the U.S. and meet buoyant global demand for functional dairy and medical nutrition, supporting margin expansion. | Ticker | 2026-02-20 | |
| BN.PA_2325a7b3 | year 2026 | 2026-01-01 | 2026-12-31 | Achievement of full-year 2026 financial guidance: +3% to +5% LFL sales growth and recurring operating income growing faster than sales. | Meeting these targets would validate the 'Renew Danone Chapter 2' strategy and support the company's transition into a 'value compounder' for investors. | Ticker | 2026-02-20 |